The ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of the clinical response to 5′-deoxy-5-fluorouridine

European Journal of Cancer

Volumn 40, Issue 10, 2004, Pages 1566-1571

  Nishina, Tomohiro ^a   Hyodo, Ichinosuke ^a   Miyaike, Jiro ^b   Inaba, Tomoki ^c   Suzuki, Seiyuu ^d   Shiratori, Yasushi ^e  

^a NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^b Saiseikai Imabari Hospital   (Japan)

^c KAGAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^d Sumitomo Beshi Hospital   (Japan)

^e OKAYAMA UNIVERSITY   (Japan)

Author keywords

5 Deoxy 5 fluorouridine; Capecitabine; Cisplatin; Dihydropyrimidine dehydrogenase; ELISA; Gastric cancer; Mitomycin C; Thymidine phosphorylase

Indexed keywords

CAPECITABINE; CISPLATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; DOXIFLURIDINE; FLUOROURACIL; MITOMYCIN C; THYMIDINE PHOSPHORYLASE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; ENDOSCOPIC BIOPSY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; METASTASIS; PREDICTION; PRIORITY JOURNAL; STOMACH CANCER;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DIHYDROURACIL DEHYDROGENASE (NADP); ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOXURIDINE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; THYMIDINE PHOSPHORYLASE; TREATMENT OUTCOME;

EID: 2942542800     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.02.019     Document Type: Article

References (27)

1. Hamburger A.W., Salmon S.E. Primary bioassay of human tumor stem cells. Science. 197:1977;461-463
2. Von Hoff D.D. He's not going to talk about in vitro predictive assays again, is he? J. Natl. Cancer Inst. 82:1990;96-101
3. Furukawa T., Yoshimura A., Sumizawa T., et al. Angiogenic factor. Nature. 356:1992;668
4. Haraguchi M., Miyadera K., Uemura K., et al. Angiogenic activity of enzymes. Natura. 368:1994;198
5. Moghaddam A., Zhang H.T., Fan T.P., et al. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc. Natl. Acad. Sci. USA. 92:1995;998-1002
6. Takebayashi Y., Akiyama S., Akiba S., et al. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J. Natl. Cancer Inst. 88:1996;1110-1117
7. Nishida M., Hino A., Mori K., Matsumoto T., Yoshikubo T., Ishitsuka H. Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues. Biol. Pharm. Bull. 19:1996;1407-1411
8. Mori K., Hasegawa M., Nishida M., et al. Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. Int. J. Oncol. 17:2000;33-38
9. ′ -deoxy-5-fluoropyrimidine nucleosides J. Med. Chem. 22:1979;1330-1335
10. ′ -deoxy-5-fluorouridine by thymidine phosphorylase in human tumors Chem. Pharm. Bull. (Tokyo). 31:1983;175-178
11. ′ -DFUR) in patients with inoperable advanced gastric cancer by immunostaining of thymidine phosphorylase/platelet-derived endothelial cell growth factor Oncology. 56:1999;215-222
12. ′ -deoxy-5-fluorouridine in the treatment of gastric cancer: a multicenter cooperative study J. Int. Med. Res. 16:1988;17B-18B
13. ′ -deoxy-5-fluorouridine and cisplatin in the treatment of advanced gastric cancer with primary foci Cancer. 72:1993;658-662
14. Naguib F.N., el Kouni M.H., Cha S. Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res. 45:1985;5405-5412
15. Heggie G.D., Sommadossi J.P., Cross D.S., Huster W.J., Diasio R.B. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 47:1987;2203-2206
16. Beck A., Etienne M.C., Cheradame S., et al. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur. J. Cancer. 30A:1994;1517-1522
17. Ishikawa T., Sekiguchi F., Fukase Y., Sawada N., Ishitsuka H. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res. 58:1998;685-690
18. Terashima M., Fujiwara H., Takagane A., et al. Role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in tumour progression and sensitivity to doxifluridine in gastric cancer patients. Eur. J. Cancer. 38:2002;2375-2381
19. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92:2000;205-216
20. Salonga D., Danenberg K.D., Johnson M., et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res. 6:2000;1322-1327
21. Kakeji Y., Maehara Y., Shibahara K., et al. Heterogeneity and clinical role of thymidine phosphorylase activity in gastric cancer. Oncol. Rep. 6:1999;1213-1216
22. Sawada N., Ishikawa T., Fukase Y., Nishida M., Yoshikubo T., Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin. Cancer Res. 4:1998;1013-1019
23. Scanlon K.J., Newman E.M., Lu Y., Priest D.G. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc. Natl. Acad. Sci. USA. 83:1986;8923-8925
24. ′ -DFUR) and mitomycin (MMC) in patients with inoperable, advanced gastirc cancer: a randomized trial comparing two dosage regimens Oncol. Rep. 3:1996;255-260
25. Ishitsuka H. Capecitabine: preclinical pharmacology studies. Investigat. New Drugs. 18:2000;343-354
26. Koizumi W., Taguchi T. A phase II study of capecitabine (Xeloda™) in patients with advanced/metastatic gastric carcinoma. Proc. Am. Soci. Clin. Oncol. 20:2001;142b. (Abstract 2320)
27. Kim T.W., Kang Y.K., Ahn J.H., et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann. Oncol. 13:2002;1893-1898